"Revlimid Litigation is delayed and the trial is now expected to begin in Q2FY21. Revlimid is a large opportunity as it could add more than $500 million net present value even in the worst case," said Credit Suisse.
Wednesday 18 December 2019
Shares Of Dr Reddy’s Laboratories Climbed By Over A Percent In Morning Trade
"Revlimid Litigation is delayed and the trial is now expected to begin in Q2FY21. Revlimid is a large opportunity as it could add more than $500 million net present value even in the worst case," said Credit Suisse.
Subscribe to:
Post Comments (Atom)
Trends On SGX Nifty Indicate A Positive Opening For The Broader Index In India
Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 31.5 points gain or 0.25 percent. The Nifty future...
-
Benchmark indices are trading higher in the pre-opening trade on Thursday. The Sensex is up 66.14 points or 0.17% at 38199.02, and the Ni... -
The Sensex is up 171.44 points at 38404.85, while Nifty is up 40.50 points at 11523.80. About 559 shares have advanced, 239 shares declin... -
Maruti Suzuki India share price added 1.5 percent in the early trade on December 17 after foreign research house Bank of America Merrill ...
No comments:
Post a Comment